Targeted therapy has become increasingly important in cancer therapy. For example, targeting the promyelocytic leukemia PML protein in leukemia has proved to be an effective treatment. PML is the core component of super-assembled structures called PML nuclear bodies (NBs). Although this nuclear megaDalton complex was first observed in the 1960s, the mechanism of its assembly remains poorly understood. We review recent breakthroughs in the PML field ranging from a revised assembly mechanism to PML-driven genome organization and carcinogenesis. In addition, we highlight that oncogenic oligomerization might also represent a promising target in the treatment of leukemias and solid tumors.

靶向治疗在癌症治疗中变得越来越重要。例如，靶向白血病中的早幼粒细胞白血病PML蛋白已被证明是一种有效的治疗方法。PML 是称为 PML 核体 (NB) 的超组装结构的核心组件。尽管这种核巨道尔顿复合体在 1960 年代首次被观察到，但其组装机制仍知之甚少。我们回顾了 PML 领域的最新突破，从修改后的组装机制到 PML 驱动的基因组组织和致癌作用。此外，我们强调致癌寡聚化也可能代表治疗白血病和实体瘤的有希望的靶点。